Arlington Medical Resources (AMR) and Decision Resources find that with the rising incidence of skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA), an overwhelming majority of surveyed physicians indicate that the most important attribute influencing antibiotic selection in skin and skin structure infections (SSSIs) is activity against MRSA. Other factors that influence drug selection include an agent's skin penetration and its ability to avoid the development of resistant pathogens.
"Physicians we surveyed also indicate that the two most important factors that influence hospital prescribing for SSSIs are recommendations from infectious disease consults and the Infectious Diseases Society of America (IDSA) guidelines. Clinicians treating patients with SSSIs look to these specialists and guidelines for direction when managing SSSI patients," stated John Lebbos, M.D., vice president of infectious diseases at Decision Resources.
The new report entitled Hospital Anti-Infectives Insight Series: Skin & Skin Structure Infections also finds that surveyed physicians state that the success of Pfizer's Zyvox and Cubist Pharmaceuticals' Cubicin is driven strongly by these agents' excellent activity against MRSA. Vancomycin remains the most commonly prescribed agent for empiric coverage of MRSA, and its use is largely driven by familiarity and local hospital guidelines. In contrast, surveyed physicians indicate that use of Zyvox and Cubicin is driven by product attributes, namely their excellent activity against MRSA activity.
About Hospital Anti-Infectives Insight Series
AMR and Decision Resources' new Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.
2008 Hospital Anti-Infectives Insight Series reports include: -- Hospital Anti-Infectives Insight Series: Nosocomial Pneumonia -- Hospital Anti-Infectives Insight Series: Skin & Skin Structure Infections -- Hospital Anti-Infectives Insight Series: U.S. Antibiotic Usage Patterns and Drivers in the ICU Setting About AMR
AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 firstname.lastname@example.org email@example.com
First Call Analyst:
SOURCE: Arlington Medical Resources; Decision Resources
CONTACT: Natalia Morales of Decision Resources, +1-781-296-2691,
firstname.lastname@example.org; or Elizabeth Marshall of Decision Resources, Inc.,